Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chronic Lymphocytic Leukemia
100%
Novel Therapeutics
100%
Prohibitin
100%
Translation Initiation
66%
CLL Cells
44%
Phosphorylation
33%
Eukaryotic Translation Initiation Factor 4E (eIF4E)
33%
Cancer Types
22%
Microenvironment
22%
In Vivo Applications
22%
TCL1
22%
Translation Rate
22%
T Cells
11%
Leukemia
11%
Clinical Parameters
11%
Cell Proliferation
11%
Murine Model
11%
CLL Patients
11%
Molecular Targets
11%
High-level Expression
11%
Cell-to-cell
11%
Western Blot
11%
Cell Viability
11%
Improved Survival
11%
Short Hairpin RNA (shRNA)
11%
Patient Samples
11%
Standard of Care
11%
Apoptosis Induction
11%
Direct Impact
11%
Mechanism of Action
11%
Adoptive Transfer
11%
Oncogene
11%
Gene Silencing
11%
Co-immunoprecipitation (co-IP)
11%
Scaffold Protein
11%
C-Myc
11%
Normal B Cells
11%
Poor Survival
11%
Pulsed SILAC
11%
ERK Phosphorylation
11%
TLR Stimulation
11%
Most Common Form
11%
Proximity Ligation Assay
11%
Nanoluciferase
11%
Flavagline
11%
MEK-ERK Pathway
11%
ETS1
11%
Translation Inhibition
11%
Raf-MEK-ERK
11%
RAF1
11%
Biochemistry, Genetics and Molecular Biology
Prohibitin
100%
Translation Initiation
66%
phosphorylation
44%
Immunoprecipitation
11%
Western Blot
11%
Oncogene
11%
Cell Proliferation
11%
Cell Viability
11%
T Cell
11%
B Cell
11%
Small Hairpin RNA
11%
Myc
11%
Scaffold Protein
11%
Pulse Rate
11%
Gene Inactivation
11%
Programmed Cell Death
11%
Small Interfering RNA
11%